• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Forma Therapeutics, CRT collaborate

Forma Therapeutics, CRT collaborate

July 11, 2013
CenterWatch Staff

Forma Therapeutics and Cancer Research Technology (CRT), the commercialization company of Cancer Research U.K., have announced a research initiative to discover tools, technologies and therapeutic drug candidates against a variety of protein homeostasis regulators called deubiquitinating enzymes (DUBs).

Forma will pair its drug discovery capabilities with CRT’s experience in translating academic discoveries through its Discovery Laboratories (CRT-DL) and the academic network of Cancer Research U.K.  principal investigators.

“This initiative with CRT and Cancer Research U.K. has the potential to accelerate our understanding of the relevant biological applications of DUBs, a key class of enzymes involved in regulating protein homeostasis,” said Steven Tregay, Ph.D., president and chief executive officer, Forma.

Protein ubiquitination is involved in many cellular processes and its regulation is controlled in part by DUBs. Ubiquitin “tags” proteins for degradation, and DUBs remove this tag, providing a tool for manipulating protein levels (protein homeostasis) in a cell. Ubiquitin biology is therefore complex and important to a broad range of human diseases. Forma and CRT-DL will leverage their combined strengths to explore the protease enzymes that regulate ubiquitin-dependent pathways implicated in cancer.

A collaborative consortium will be formed consisting of FormaTherapeutics and up to 10 Forma Asset Discovery and Development Company (ADDCos) subsidiaries, CRT-DL and initially five PIs, including professors Michael Clague and Sylvie Urbé at the University of Liverpool; Dr. Benedikt Kessler at The University of Oxford; Dr. David Komander at the Medical Research Council, Laboratory of Molecular Biology, Cambridge, U.K.; and Dr. Huib Ovaa at the Chemical Biology Laboratory, Netherlands Cancer Institute.

These investigators will focus on furthering the consortium’s understanding of biological and structural insights of DUBs and assist the discovery teams to ensure the most relevant screening technologies and secondary characterization assays are deployed for selection of lead candidates. Forma will provide research funding support and defined compensation payments for DUB-specific ADDCo programs that achieve specified milestones.

“This vehicle allows our nonprofit collaborators to access a capital efficient engine operating at scale, attain financial returns mirroring their contributions and collectively advance medical science within the framework of a unified team,” said Rob Sarisky, chief business officer, Forma Therapeutics.

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • MachineLearning-360x240.png

    Industry Using AI/ML to Improve Data, Quality and Trial Management, Survey Says

  • VirtualTraining-360x240.png

    Virtual Training Evolves into More In-Depth Learning, Improved Communications

  • SurveywBlueBackground-360x240.png

    Mid-Study Updates Delay Trials At Least a Month, CSDD Report Finds

  • Real-TimeData-360x240.png

    Real-Time Data Helped Sponsors Respond to Sites’ Needs During the Pandemic

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing